Skip to main content
. 2016 Jul 5;23(7):564–575. doi: 10.1128/CVI.00665-15

TABLE 2.

S. sonnei LPS-specific immune responses in 13 volunteers after WRSS1 vaccination and subsequent S. sonnei 53G challenge

Volunteer serial no. Postimmunization
Postchallengee
Clinical symptom(s) related to challenge
WRSS1 sheddinga (days) ASC count/106 PBMCsb
Fold increase inc:
53G sheddinga (days) ASC count/106 PBMCsb
Fold increase in serum Ab titersc
Fold increase in fecal IgA titers/100 μg of T-IgAc
Serum Ab titers
Fecal IgA titers/100 μg of T-IgA
IgA IgG IgM IgA IgG IgA IgG IgM IgA IgG
1 8 138 30 80 75 5 490 160 130 11
2 1 4 9 3 530 600 4 8
3 9 1,290 290 140 4 29 6 6,870 3,980 1,710 64 22 9 Dysentery
4 7 79 23 7 4 144 35 14 Myalgia, headache, malaised
5 1 7 5
6 6 20 6 5 Dysentery
7 0 1 46 14 4
8 0 2 930 1,000 100 36 20
9 0 0
10 0 5 4 4,730 7,480 1,070 169 135 Diarrhea, fever
11 2 12 10
12 6 8 4 8
13 11 420 470 4 7
a

Number of days of shedding based on culture and/or PCR of fecal sample.

b

Only ASC counts of ≥5 ASCs per 106 PBMCs are shown.

c

A ≥4-fold increase in antibody titers was considered significant. Ab, antibody.

d

Volunteer serial number 4 had AE but did not meet the criteria of clinical endpoint (diarrhea, dysentery, fever, or shigellosis).

e

Volunteers 11, 12, and 13 were not challenged with strain 53G.